Prevention and management of cardiovascular disease in adults with cancer: an International Cardio-Oncology Society (IC-OS) and Multinational Association of Supportive Care in Cancer (MASCC) clinical practice statement
Open Access
- 29 May 2026
- journal article
- review article
- Published by Springer Nature in Cardio-Oncology
- Vol. 12 (1) , 71
Abstract
Cardiovascular (CV) toxicity is prevalent in cancer survivors due to shared risk factors, direct CV injury from cancer therapy (CT), and development/exacerKeywords
This publication has 41 references indexed in Scilit:
- Diagnosis and Management of Cardiovascular Adverse Effects of Targeted Oncology Therapies: Bruton’s Tyrosine Kinase, Immune Checkpoint, and Vascular Endothelial Growth Factor Inhibitors: 2025 ACC Concise Clinical GuidanceJACC, 2025
- Reducing the impact of cardiovascular disease in older people with cancer: a qualitative study of healthcare providersJournal of Cancer Survivorship, 2023
- Global Longitudinal Strain for the Early Detection of Chemotherapy-Induced Cardiotoxicity: A Systematic Review and Meta-analysisClinical Oncology, 2022
- Role of Serum Biomarkers in Cancer Patients Receiving Cardiotoxic Cancer Therapies: A Position Statement from the Cardio-Oncology Study Group of the Heart Failure Association and the Cardio-Oncology Council of the European Society of CardiologyEuropean Journal of Heart Failure, 2020
- Role of Cardiovascular Imaging in Cancer Patients Receiving Cardiotoxic Therapies: A Position Statement on Behalf of the Heart Failure Association (HFA), the European Association of Cardiovascular Imaging (EACVI) and the Cardio-Oncology Council of the European Society of Cardiology (ESC)European Journal of Heart Failure, 2020
- Baseline Cardiovascular Risk Assessment in Cancer Patients Scheduled to Receive Cardiotoxic Cancer Therapies: A Position Statement and New Risk Assessment Tools from the Cardio-Oncology Study Group of the Heart Failure Association of the European Society of Cardiology in Collaboration with the International Cardio-Oncology SocietyEuropean Journal of Heart Failure, 2020
- Management of cardiac disease in cancer patients throughout oncological treatment: ESMO consensus recommendationsAnnals of Oncology, 2020
- A Cardio-Oncology Cardiovascular Prevention FrameworkJACC: Cardiooncology, 2019
- Efficacy of Dexrazoxane in Preventing Anthracycline Cardiotoxicity in Breast CancerJACC: Cardiooncology, 2019
- Use of Myocardial Strain Imaging by Echocardiography for the Early Detection of Cardiotoxicity in Patients During and After Cancer ChemotherapyJACC, 2014